Who Optimizes SG&A Costs Better? Catalent, Inc. or Galapagos NV

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of the pharmaceutical and biotechnology sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Catalent, Inc. and Galapagos NV, two industry players, have shown contrasting trends in their SG&A expenses from 2014 to 2023. Catalent, Inc. has seen a steady increase in SG&A costs, peaking at approximately $935 million in 2023, reflecting a growth of nearly 180% over the decade. In contrast, Galapagos NV's expenses have fluctuated, with a notable peak in 2022 at around $240 million, before dropping significantly in 2023. This divergence highlights Catalent's aggressive expansion strategy, while Galapagos NV appears to be optimizing its costs more conservatively. The absence of data for Galapagos NV in 2024 suggests a potential shift or restructuring in their financial strategy. Understanding these trends provides valuable insights into each company's operational focus and market positioning.